MannKind is trading 5% up today at $3.99 as investors position ahead of its August 5, 2026, second-quarter earnings report.
- Traders are betting on solid commercial execution for flagship therapies, with consensus calling for approximately $108.8 million in revenue and a narrow loss.
- The move is further supported by a broader rally in biotech and U.S. equities, providing tailwinds for the stock’s rebound from recent weakness.